Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Exicure nets $59.45mm through public offering

Executive Summary

Exicure Inc. (using its spherical nucleic acid (SNA) technology to develop treatments for cancer, inflammatory diseases, and genetic disorders) netted $59.45mm through a public offering of 31.6mm common shares (including the overallotment) at $2. Proceeds will support advancement of immuno-oncology candidate AST008 into Phase Ib/IIa and will also fund early development of an SNA compound for an undisclosed neurological condition. Concurrent with the offering, Exicure uplisted from the OTCBB to the Nasdaq Capital Market.
Deal Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Drug Discovery Tools
      • Genomics-Proteomics
    • Gene Therapy, Cell Therapy
    • Nanotechnology, Chips, etc.
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies